Radioiodine News and Research

RSS

Iodine-131 (131I), also called radioiodine (though many other radioactive isotopes of this element are known), is an important radioisotope of iodine. It has a radioactive decay half life of about eight days. Its uses are mostly medical and pharmaceutical.

Embryonic stem cells used to recreate thyroid cancer histotypes

A recent Nature Communications study revealed the recapitulating capacity of human embryonic stem cells (hESCs) to elucidate the cellular hierarchy of the thyroid gland. Furthermore, these cells possessed the capacity to reproduce the oncogenic process using the CRISPR-based genetic editing method.

14 Mar 2023

Fusion oncogenes associated with more invasive pediatric thyroid cancers, study says

Fusion oncogenes, such as RET- and NTRK-gene fusions, are associated with more invasive pediatric thyroid cancers, correlating with the highest risk of metastases and a lower likelihood of achieving remission one year after initial therapy, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP).

31 Jan 2022

Global nuclear medicine community shares approaches to contain the spread of COVID-19

In an effort to provide safer working environments for nuclear medicine professionals and their patients, clinics across five continents have shared their approaches to containing the spread of COVID-19 in a series of editorials, published ahead of print in The Journal of Nuclear Medicine.

1 Apr 2020

New guidance will help improve outcomes for patients with hyperthyroidism

Radioactive iodine is to be recommended as the frontline treatment for patients with thyroid gland overactivity caused by conditions such as Graves’ disease, following an evidence review led by University of Birmingham researchers.

28 Jan 2020

Caution is advised in interpreting the findings on radioiodine therapy for hyperthyroidism

Caution is advised in interpreting the findings of the recent JAMA Internal Medicine publication1 on radioactive iodine treatment for hyperthyroid patients and cancer mortality.

13 Dec 2019

Researchers develop technique to track proteins on the surfaces of endoplasmic reticulum in cells

Researchers from Kanazawa University on the development of a technique to closely track a specific protein on the surfaces of endoplasmic reticulum (ER) in cells. Their findings are published in Bioorganic and Medicinal Chemistry.

17 Jun 2019

Low risk thyroid cancer patients can be treated with smaller amount of radiation, suggests study

Thyroid cancer patients whose disease is at low risk of returning can be treated safely with a smaller amount of radiation following surgery, according to results from the world's longest running trial to investigate this.

5 Nov 2018

International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

Led by researchers at the University of Pittsburgh School of Medicine, an international panel of pathologists and clinicians has reclassified a type of thyroid cancer to reflect that it is noninvasive and has a low risk of recurrence. The name change, described today in JAMA Oncology, is expected to reduce the psychological and medical consequences of a cancer diagnosis, potentially affecting thousands of people worldwide.

16 Apr 2016

New ATA guidelines for managing adult patients with thyroid nodules and DTC published in Thyroid journal

New, evidence-based recommendations from the American Thyroid Association will help guide clinicians in managing patients with thyroid nodules, a common disorder that requires evaluation to distinguish benign nodules from malignancy, interpret biopsy results and molecular marker studies, and initiate risk assessment and cancer screening.

15 Oct 2015

Intensive therapy needed in paediatric triiodothyronine-predominant Graves' disease

Paediatric patients with triiodothyronine-predominant Graves' disease develop severe disease that needs increased doses of antithyroid drugs, a study shows.

1 Apr 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause.

7 Oct 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine.

31 Jan 2014

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

The American Thyroid Association (ATA) recommends against the routine use of radioactive iodine after surgery to remove the thyroid in patients with low-risk papillary thyroid cancer (PTC).

17 Oct 2013

Ohio State University researchers awarded NCI grant to further study thyroid cancer

The National Cancer Institute has awarded a five-year, $11.3 million grant to a team of researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute to further their studies on thyroid cancer.

5 Sep 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

New guidance on radioiodine therapy use after radiographic studies

Researchers have provided new evidence that could act as a guide for the use of radioiodine therapy after patients have undergone radiographic imaging studies that use iodine as a contrasting agent.

30 Apr 2013

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, has conducted the first combination treatment of microwave ablation and radiotherapy.

10 Apr 2013